SCHEMBL14735522

SCHEMBL14735522

C#Cc1ccc2c(C=O)c[nH]c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.49
CYP2A6 P11509 2/20 0.39
IMPDH2 P12268 1/20 0.39
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
HASPIN Q8TF76 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
TRIM24 O15164 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
PIM3 Q86V86 9/20 0.35
PIM1 P11309 7/20 0.35
PIM2 Q9P1W9 2/20 0.35
PLG P00747 1/20 0.34
PLAU P00749 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
CHEK1 O14757 1/20 0.32
CCR1 P32246 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29958275 0.84 KMT2A (0.49) KMT2ACYP2A6IMPDH2CCNT1CDK9
SCHEMBL5263827 0.76 KMT2A (0.54) KMT2ACYP2A6IMPDH2CCNT1CDK9
SCHEMBL29953043 0.75 KMT2A (0.53) KMT2ACYP2A6IMPDH2ALDH1A1KDM4E
SCHEMBL1714533 0.75 KMT2A (0.53) KMT2ACYP2A6IMPDH2CCNT1CDK9
SCHEMBL29952450 0.75 KMT2A (0.53) KMT2ACYP2A6IMPDH2CCNT1CDK9
SCHEMBL13132293 0.75 KMT2A (0.53) KMT2ACYP2A6IMPDH2ALDH1A1KDM4E
SCHEMBL23726193 0.71 KMT2A (0.49) KMT2ACYP2A6IMPDH2CCNT1CDK9
SCHEMBL29955200 0.71 KMT2A (0.49) KMT2ACYP2A6IMPDH2CCNT1CDK9
SCHEMBL14735486 0.70 KMT2A (0.51) KMT2ACYP2A6IMPDH2CCNT1CDK9
SCHEMBL29951425 0.70 KMT2A (0.51) KMT2ACYP2A6IMPDH2CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103391936-B Carcinostatic agent THE UNIVERSITY OF TOKYO (JP) 2016-04-27 CN disclosed
EP-2565192-B9 ANTICANCER AGENT UNIV TOKYO (JP) 2015-11-25 EP disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 US disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 US disclosed
EP-2565192-B1 ANTICANCER AGENT UNIV TOKYO (JP) 2015-08-12 EP disclosed
CN-103391936-A Anticancer agent NAT UNIV CORP UNIV TOKYO 2013-11-13 CN disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 US disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 US disclosed
EP-2565192-A1 ANTICANCER AGENT The University of Tokyo (JP) 2013-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102776-A1 ANTICANCER AGENT PIM1, PIM3, PIM2 KMT2A 576/4885CYP2A6 2842/4885IMPDH2 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.